Literature DB >> 28322198

Multiple and Recurrent Squamous Cell Carcinoma of the Oral Cavity After Graft-Versus-Host Disease.

Xiuhong Weng1, Yuzhen Xing1, Bo Cheng2.   

Abstract

Oral squamous cell carcinoma (OSCC) is one of the most common secondary solid tumors in patients who have undergone hematopoietic stem cell transplantation (HSCT). However, according to previous reports, multiple and recurrent OSCC is very rare. The presented case shows the susceptibility to the development of secondary malignancies, particularly oral cancer, of patients who present with chronic graft-versus-host disease after HSCT. OSCC after HSCT appears to be more invasive and has a tendency to recur, with a poor prognosis. Therefore, regular and thorough evaluations of the oral mucosa are recommended for all patients who undergo bone marrow transplantation and have chronic graft-versus-host disease.
Copyright © 2017 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28322198     DOI: 10.1016/j.joms.2017.02.012

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  3 in total

Review 1.  MAIT cells and their implication in human oral diseases.

Authors:  Qin Jiang; Fang Wang; Jing-Ya Yang; Gang Zhou
Journal:  Inflamm Res       Date:  2022-07-04       Impact factor: 6.986

2.  Occurrence of quadruple squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation for leukemia: A case report.

Authors:  Chunhong Hu; Xue Wang; Yue Pan; Long Shu; Fang Wu
Journal:  Oncol Lett       Date:  2021-03-02       Impact factor: 3.111

3.  Repeated Occurrence and Recurrence of Secondary Oral Solid Cancers after Hematopoietic Stem Cell Transplantation for Leukaemia: Long-Term Follow-Up.

Authors:  Takumi Takahashi; Miki Yamada; Keisuke Sawada; Nami Nakayama; Yosuke Iijima; Shunsuke Hino; Takahiro Kaneko; Norio Horie
Journal:  Case Rep Dent       Date:  2022-08-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.